8-K: Calidi Biotherapeutics Secures $3.9 Million in Direct Offering and Private Placement

Calidi Biotherapeutics closes a $3.9 million registered direct offering and concurrent private placement to fund working capital and advance clinical programs.

Summary

• Calidi Biotherapeutics has closed a registered direct offering and concurrent private placement, raising approximately $3.9 million before fees.
• The offering included 3,325,000 shares of common stock and pre-funded warrants to purchase up to 2,728,000 shares.
• Series G warrants to purchase up to 6,053,000 shares of common stock were also issued in a concurrent private placement.
• The offering price was $0.65 per share (or pre-funded warrant) with a warrant exercise price of $0.6954.
• Pre-funded warrants are exercisable immediately at $0.001 per share, while Series G warrants are exercisable six months after issuance and expire in seven and a half years.
• Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent.
• Calidi intends to use the net proceeds for working capital, general corporate purposes, and to advance its pre-clinical and clinical programs.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is raising capital, which can be seen as a positive, it also involves dilution for existing shareholders. The use of proceeds for working capital and clinical programs is a positive sign for future growth.

Positives

• The capital raise provides Calidi with additional funding for working capital and to advance its clinical programs.
• The use of pre-funded warrants allows investors flexibility in managing their ownership.
• The involvement of Ladenburg Thalmann & Co. Inc. as placement agent adds credibility to the offering.

Risks

• The offering may dilute existing shareholders' equity.
• The exercise of warrants could further dilute ownership and put downward pressure on the stock price.
• The company's success is dependent on the success of its clinical programs, which are subject to regulatory and clinical trial risks.

Future Outlook

Calidi intends to use the net proceeds from the offerings for working capital and for general corporate purposes and to advance its pre-clinical and clinical programs.

Industry Context

This capital raise reflects the ongoing need for biotechnology companies to secure funding for research and development, particularly in the competitive immuno-oncology space. The structure of the offering, including common stock, pre-funded warrants, and Series G warrants, is a common approach to attract different types of investors.

Comparison to Industry Standards

• Comparable companies in the biotechnology sector, such as Iovance Biotherapeutics and Gritstone Bio, have also utilized registered direct offerings and private placements to raise capital.
• The terms of the offering, including the warrant coverage and exercise prices, are within the typical range for similar transactions in the small-cap biotech space.
• The use of a shelf registration statement allows for a more efficient capital raising process compared to traditional underwritten offerings.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• Employees may benefit from the company's ability to fund ongoing operations and research.
• The company's ability to advance its clinical programs could benefit patients in the long term.

Next Steps

• The closing of the registered direct offering and the concurrent private placement is expected to occur on or about March 31, 2025, subject to the satisfaction of customary closing conditions.
• Calidi intends to use the net proceeds from the offerings for working capital and for general corporate purposes and to advance its pre-clinical and clinical programs.

Key Dates

Keywords

Calidi Biotherapeutics, registered direct offering, private placement, common stock, pre-funded warrants, Series G warrants, Ladenburg Thalmann, capital raise, immunotherapy, oncology